2-benzyloxycarbonyl-1,2,3,4-tetrahydropyrido[3,4-b]indole-1-carboxylic acid | 128019-27-2

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 2-benzyloxycarbonyl-1,2,3,4-tetrahydropyrido[3,4-b]indole-1-carboxylic acid
• 英文别名: 1,3,4,9-tetrahydro-beta-carboline-1,2-dicarboxylic acid 2-benzyl ester；2-phenylmethoxycarbonyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-1-carboxylic acid
• CAS: 128019-27-2
• 化学式: C₂₀H₁₈N₂O₄
• 分子量: 350.374
• InChiKey: ZCPZVOOVXHGIPR-UHFFFAOYSA-N

物化性质

• 沸点：
  617.6±55.0 °C(Predicted)
• 密度：
  1.399±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  82.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-benzyloxycarbonyl-1,2,3,4-tetrahydropyrido[3,4-b]indole-1-carboxylic acid 在 sodium acetate 、 二异丁基氢化铝 、 sodium cyanoborohydride 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 异丙醇 、 甲苯 为溶剂， 反应 105.0h， 生成 1-{[tert-butoxycarbonyl-((S)-cyclopentyloxycarbonyl-phenyl-methyl)-amino]-methyl}-1,3,4,9-tetrahydro-beta-carboline-2-carboxylic acid benzyl ester
  参考文献：
  名称：

  WO2006/117549

  摘要：

  公开号：
• 作为产物：
  描述：

  色胺盐酸盐 在 氢氧化钾 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 4.5h， 生成 2-benzyloxycarbonyl-1,2,3,4-tetrahydropyrido[3,4-b]indole-1-carboxylic acid
  参考文献：
  名称：

  WO2006/117549

  摘要：

  公开号：

文献信息

• Amino acid derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US05157041A1

  公开（公告）日：1992-10-20

  Compounds of the formula ##STR1## wherein R.sup.1 is alkoxycarbonyl, aralkoxycarbonyl, alkanoyl, cycloalkylcarbonyl, aralkanoyl, aroyl, heterocyclylcarbonyl, alkylsulphonyl, arylsulphonyl, monoaralkylcarbamoyl, cinnamoyl or .alpha.-aralkoxycarbonylaminoalkanoyl and R.sup.2 is hydrogen or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached represent a cyclic imide group of the formula ##STR2## in which P and Q together represent an aromatic system; R.sup.3 is alkyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl, cyanoalkyl, alkyl- sulphinylalkyl, carbamoylalkyl or alkoxycarbonylalkyl or, when n stands for zero, R.sup.3 can also represent alkylthioalkyl or, when n stands for 1, R.sup.3 can also represent alkylsulphonylalkyl; R.sup.4 is alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl; R.sup.5 is hydrogen and R.sup.6 is hydroxy or R.sup.5 and R.sup.6 together represent oxo; R.sup.7 and R.sup.8 together represent a trimethylene or tetramethylene group which is optionally substituted by hydroxy, alkoxycarbonylamino or acylamino or in which one --CH.sub.2 -- group is replaced by --NH--, --N(alkoxycar- bonyl)--, --N(alkyl)-- or --S-- or which carries a fused cycloalkane, aromatic or heteroaromatic ring; and R.sup.9 is alkoxycarbonyl, monoalkylcarbamoyl, monoaralkylcarbamoyl, monoarylcarbamoyl or a group of the formula ##STR3## in which R.sup.10 and R.sup.11 each represent alkyl; and their pharmaceutically acceptable acid addition salts inhibit proteases of viral origin and can be used as medicaments for the treatment or prophylaxis of viral infections. They can be manufactured according to generally known procedures.

  式##STR1##中的化合物，其中R.sup.1是烷氧羰基，芳基烷氧羰基，烷酰基，环烷基羰基，芳基烷酰基，芳酰基，杂环烷基羰基，烷基磺酰基，芳基磺酰基，单芳基烷基氨基甲酰基，肉桂酰基或α-芳基烷氧羰基氨基烷酰基，R.sup.2是氢或R.sup.1和R.sup.2与它们连接的氮原子一起表示式##STR2##中的环酰亚胺基团，其中P和Q一起表示芳香系统；R.sup.3是烷基，环烷基，芳基，芳基烷基，杂环烷基烷基，氰基烷基，烷基磺酰基烷基，氨基甲酰基烷基或烷氧羰基烷基，或者当n为零时，R.sup.3也可以表示烷基硫代烷基，或者当n为1时，R.sup.3也可以表示烷基磺酰基烷基；R.sup.4是烷基，环烷基，环烷基烷基，芳基或芳基烷基；R.sup.5是氢，R.sup.6是羟基或R.sup.5和R.sup.6一起表示氧代；R.sup.7和R.sup.8一起表示可选地由羟基，烷氧羰基氨基或酰胺基取代的三亚甲基或四亚甲基基团，或其中一个--CH.sub.2--基团被--NH--，--N(烷氧羰基)--，--N(烷基)--或--S--取代，或者带有融合的环烷烃，芳香或杂芳环；R.sup.9是烷氧羰基，单烷基氨基甲酰基，单芳基烷基氨基甲酰基，单芳基氨基甲酰基或式##STR3##中的基团，其中R.sup.10和R.sup.11各自表示烷基；它们的药学上可接受的酸盐抑制病毒起源的蛋白酶，并可用作治疗或预防病毒感染的药物。它们可以根据通常已知的程序制造。
• ENZYME INHIBITORS
  申请人：Davidson Alan Hornsby

  公开号：US20140163042A1

  公开（公告）日：2014-06-12

  Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R 2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, —C(═O), —S(═O) 2 —, —C(═O)O—, —C(O)NR 3 —, —C(═S)—NR 3 , —C(═NH)NR 3 or —S(═O) 2 NR 3 — wherein R 3 is hydrogen or optionally substituted C 1 -C 6 alkyl; L 1 is a divalent radical of formula -(Alk 1 ) m (Q) n (Alk 2 ) p - wherein m, n and p are independently 0 or 1, Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula —X 2 -Q 1 - or -Q 1 -X 2 — wherein X 2 is —O—, S— or NR A — wherein R A is hydrogen or optionally substituted C 1 -C 3 alkyl, and Q 1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, Alk 1 and Alk 2 independently represent optionally substituted divalent C 3 -C 7 cycloalkyl radicals, or optionally substituted straight or branched, C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene radicals which may optionally contain or terminate in an ether (—O—), thioether (—S—) or amino (—NR A —) link wherein R A is hydrogen or optionally substituted C 1 -C 3 alkyl; X 1 represents a bond; —C(═O); or —S(═O) 2 —; —NR 4 C(═O)—, —C(═O)NR 4 —, —NR 4 C(═O)NR 5 —, —NR 4 S(═O) 2 —, or —S(═O) 2 NR 4 — wherein R 4 and R 5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl; z is 0 or 1; A represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system wherein the radicals R 1 R 2 NH—Y-L 1 -X 1 -[CH 2 ] Z — and HONHCO-[LINKER]- are attached different ring atoms; and -[Linker]- represents a divalent linker radical linking a ring atom in A with the hydroxamic acid group CONIIOII, the length of the linker radical, from the terminal atom linked to the ring atom of A to the terminal atom linked to the hydroxamic acid group, is equivalent to that of an unbranched saturated hydrocarbon chain of from 3-10 carbon atoms.

  式(I)的化合物是组蛋白去乙酰化酶活性抑制剂，可用于治疗癌症等疾病，其中R1是羧酸基（-COOH）或可由一个或多个细胞内羧酸酯酶水解为羧酸基的酯基；R2是天然或非天然α氨基酸的侧链；Y是键，-C（=O），-S（=O）2-，-C（=O）O-，-C（=O）NR3-，-C（=S）-NR3，-C（=NH）NR3或-S（=O）2NR3-，其中R3是氢或可选取代的C1-C6烷基；L1是式-(Alk1)m(Q)n(Alk2)p-的二价基团，其中m、n和p独立地为0或1，Q是（i）一个可选取代的二价单环或双环碳环或杂环基团，具有5-13个环成员，或（ii）在m和p均为0的情况下，是式-Q1-X2-或-X2-Q1-的二价基团，其中X2是-O-，-S-或-NRA-，其中RA是氢或可选取代的C1-C3烷基，Q1是可选取代的二价单环或双环碳环或杂环基团，具有5-13个环成员，Alk1和Alk2独立地表示可选取代的二价C3-C7环烷基基团，或可选取代的直链或支链，C1-C6烷基，C2-C6烯基或C2-C6炔基基团，其可以可选地含有或终止于醚（-O-），硫醚（-S-）或氨基（-NRA-）链，其中RA是氢或可选取代的C1-C3烷基；X1表示键，-C（=O）或-S（=O）2-；-NR4C（=O）-，-C（=O）NR4-，-NR4C（=O）NR5-，-NR4S（=O）2-或-S（=O）2NR4-，其中R4和R5独立地为氢或可选取代的C1-C6烷基；z为0或1；A表示可选取代的单环、双环或三环碳环或杂环系统，其中基团R1R2NH-Y-L1-X1-[CH2]Z-和HONHCO-[LINKER]-附着在不同的环原子上；-[Linker]-表示将A中的一个环原子与羟酰胺酸基团CONIIOII连接的二价连接基团，连接基团的长度，从连接到A环原子的末端原子到连接到羟酸胺基团的末端原子，相当于从3-10个碳原子的直链饱和碳氢链的长度。
• Enzyme Inhibitors
  申请人：Davidson Alan Hornsby

  公开号：US20090291978A1

  公开（公告）日：2009-11-26

  Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R 2 is the side chain of a natural or non-natural alpha amino acid; Y is a bond, C(═O)—, —S(═O) 2 —, —C(—O)O—, —C(O)NR 3 —, —C(═S)—NR 3 , —C(═NH)NR 3 or —S(═O) 2 NR 3 — wherein R 3 is hydrogen or optionally substituted C 1 -C 6 alkyl; L is a divalent radical of formula -(Alk 1 ) m (O) n (Alk 2 ) p — wherein m, n and p are independently 0 or 1, Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula —X 2 -Q 1 - or -Q 1 -X 2 — wherein X 2 is —O—, S— or NR A — wherein R A is hydrogen or optionally substituted C 1 -C 3 alkyl, and Q 1 is an optionally substituted divalent mono- or bicyclic carbocyclic or hetero-cyclic radical having 5-13 ring members, AIk 1 and AIk 2 independently represent optionally substituted divalent C 3 -C 7 cycloalkyl radicals, or optionally substituted straight or branched, C 1 -C 6 alkylene, C 2 -C 6 alkenylene, or C 2 -C 6 alkynylene radicals which may optionally contain or terminate in an ether (—O—), thioether (—S—) or amino (—NR A -) link wherein R A is hydrogen or optionally substituted C 1 -C 3 alkyl; X represents a bond; —C(═O); or —S(═O) 2 —; —NR 4 C(═O)—, —C(═O)NR 4 —, —NR 4 C(═O)NR 5 —, —NR 4 S(═O) 2 —, or —S(═O) 2 NR 4 — wherein R 4 and R 5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl; z is 0 or 1; A represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system wherein the radicals R 1 R 2 NH—Y-L 1 -X 1 —[CH 2 ] z — and HONHCO-[LINKER]- are attached different ring atoms; and -[Linker]- represents a divalent linker radical linking a ring atom in A with the hydroxamic acid group CONHOH, the length of the linker radical, from the terminal atom linked to the ring atom of A to the terminal atom linked to the hydroxamic acid group, is equivalent to that of an unbranched saturated hydrocarbon chain of from 3-10 carbon atoms.

  式(I)的化合物是组蛋白去乙酰化酶抑制剂，可用于治疗癌症等疾病，其中R1是羧酸基（-COOH）或一个可被一个或多个细胞内羧酸酯酶水解为羧酸基的酯基；R2是天然或非天然α氨基酸的侧链；Y是键，C（═O）—，—S（═O）2—，—C（—O）O—，—C（O）NR3—，—C（═S）—NR3，—C（═NH）NR3或—S（═O）2NR3—，其中R3是氢或可选择性取代的C1-C6烷基；L是式-(Alk1)m(O)n(Alk2)p-的二价基团，其中m、n和p分别独立为0或1；Q是（i）一个可选择性取代的二价单环或双环碳环或杂环基团，其具有5-13个环成员，或（ii）在m和p都为0的情况下，是式—X2-Q1-或-Q1-X2—的二价基团，其中X2是—O—，S—或NRA—，其中RA是氢或可选择性取代的C1-C3烷基，Q1是一个可选择性取代的二价单环或双环碳环或杂环基团，其具有5-13个环成员，Alk1和Alk2独立地表示可选择性取代的二价C3-C7环烷基基团，或可选择性取代的直链或支链C1-C6烷基、C2-C6烯基或C2-C6炔基基团，其可以选择性地包含或终止于醚（-O-）、硫醚（-S-）或氨基（-NRA-）链，其中RA是氢或可选择性取代的C1-C3烷基；X表示键，—C（═O）；或—S（═O）2—；—NR4C（═O）—，—C（═O）NR4—，—NR4C（═O）NR5—，—NR4S（═O）2—或—S（═O）2NR4—，其中R4和R5独立地为氢或可选择性取代的C1-C6烷基；z为0或1；A表示可选择性取代的单环、双环或三环碳环或杂环系统，其中基团R1R2NH—Y-L1-X1—[CH2]z—和HONHCO-[LINKER]-附着于不同的环原子上；-[Linker]-表示连接A中的一个环原子与羟酰胺酸基团CONHOH的二价连接基团，连接基团的长度，从连接到A环原子的末端原子到连接到羟酸胺基团的末端原子，相当于3-10个碳原子的直链饱和烃链的长度。
• Enzyme inhibitors
  申请人：Chroma Therapeutics Ltd.

  公开号：US07939666B2

  公开（公告）日：2011-05-10

  Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers.

  公式（I）的化合物是组蛋白去乙酰化酶活性的抑制剂，并且在治疗癌症等方面非常有用。
• EP2301939A1
  申请人：——

  公开号：EP2301939A1

  公开（公告）日：2011-03-30